Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vical raises $20 million to develop swine flu vaccine

This article was originally published in Scrip

Executive Summary

Vical has secured a further $4.6 million from institutional investors to develop a swine flu vaccine against H1N1 influenza after raising $15.4 million of securities in a registered direct offering from two investors, including Federated Kaufmann Fund, last week. Vical planned to sell around 6.7 million shares of its common stock and options to buy up to 3.3 million additional shares.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC002334

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel